Be-Sheng Kuo
Corporate Officer/Principal at AbGenomics International, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leewen Lin | M | - |
AbGenomics International, Inc.
 AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Shih-Yao Lin | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Ruth C. S. Li | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Patrick Yang | M | 75 |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Corazon Sanders | M | 67 |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Hazel T. Y. Cheng | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Yung-Hua Chung | M | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
| Chia-Jung Yang | F | - |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edward W. Mehrer | M | 85 |
Marion Merrell Dow, Inc.
| 4 years |
| John Dunn | M | 72 |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 1 years |
| Phillip Schneider | M | 68 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 16 years |
| Mark E. Erwin | M | 59 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 4 years |
| Sangtae Kim | M | - |
Parke-Davis Pharmaceutical Research, Inc.
| 2 years |
| John J. Harrington | M | - |
Marion Merrell Dow, Inc.
| 5 years |
| David C. Furlano | M | - |
Parke-Davis Pharmaceutical Research, Inc.
| 5 years |
| Hal Craig | M | - |
Marion Merrell Dow, Inc.
| 3 years |
| Susan E. Barrowcliffe | F | 66 |
Marion Merrell Dow, Inc.
| 4 years |
| E. J. Brandreth | M | - |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 7 years |
| Richard Donaldson | M | - |
Marion Merrell Dow, Inc.
| 4 years |
| Gregory D. Flexter | M | 68 |
Marion Merrell Dow, Inc.
| - |
| Israel Rios | M | 77 |
Marion Merrell Dow, Inc.
| 9 years |
| Howard L. Foyt | M | 69 |
Parke-Davis Pharmaceutical Research, Inc.
| 4 years |
| Arturo Molina | M | 65 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 1 years |
| Alice M. Wei | F | 60 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 9 years |
| James A. Buzard | M | 97 |
Marion Merrell Dow, Inc.
| 1 years |
| Benjamin McGraw | M | 75 |
Marion Merrell Dow, Inc.
| 11 years |
| Vaughn M. Kailian | M | 79 |
Marion Merrell Dow, Inc.
| 23 years |
| David B. Sharrock | M | 87 |
Marion Merrell Dow, Inc.
| 4 years |
| Lesa Mitchell | F | - |
Marion Merrell Dow, Inc.
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 29 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Be-Sheng Kuo
- Personal Network
